CurrentCapital BluecrossPolicy MP 4.004

Negative Pressure Wound Therapy in the Outpatient Setting

Defines medical necessity criteria, investigational indications, product variations, contraindications, monitoring, and coding guidance for powered and single-use NPWT in the outpatient setting for Capital Blue Cross products (MP 4.004). This part (1 of 2) includes background, indications for initiation and continuation, contraindications, monitoring frequency, definitions, regulatory status, evidence summary, and partial coding lists.

Policy Summary

PayerCapital Bluecross

PolicyNegative Pressure Wound Therapy in the Outpatient Setting

Policy CodePolicy MP 4.004

Change TypeRevisedadministrativeclarified

Effective DateOct 1, 2025

Next Review Date

Key ActionProviders must document a comprehensive wound care program and perform an initial therapeutic trial of powered NPWT of not less than 2 weeks with documented objective wound improvement for continuation.

SourceLink

POLICY UPDATE CHANGES

Updated criteria including but not limited to single use devices are now INV and chronic being defined in this policy as greater than 90 days.

Frequency of monitoring changed from every 14 days to monthly.

Added/deleted ICD-10 codes from New Code Process with effective date 10/01/2024 and 10/01/2025 entries.

Removed Benefit Variations Section and updated Disclaimer.

3Primary medically necessary indications listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Policy MP 4.004 addresses outpatient Negative Pressure Wound Therapy (NPWT). Effective date: 10/1/2025. Scope: defines medical necessity criteria, investigational indications, product variations, contraindications, monitoring, and coding guidance for powered and single-use NPWT in the outpatient setting. Coverage stance is mixed: select uses of powered NPWT are considered medically necessary when criteria are met (see initiation and continuation requirements), while other uses — including single-use (disposable) NPWT systems and certain procedure codes — are designated investigational/not covered.

Surface policy thresholds and quick facts

Initial therapeutic trial duration>= 14 days

Monitoring frequency during NPWTNot less than every 14 days (policy states continuation should be monitored on a frequency of not less than every 14 days)

Chronic definition> 90 days

Primary medically necessary indications (count)3 (chronic stage III/IV pressure ulcers; nonhealing wounds with underlying conditions; traumatic/surgical wounds with exposed bone/cartilage/tendon/foreign material)

Investigational categories (count)3 (therapeutic trials for other acute/chronic wounds except noted; single-use NPWT systems powered or nonpowered; continuation when no objective improvement or contraindications)

Procedure codes moved to investigational2 (97607, 97608) — also A9272 listed investigational

Medical Necessity — Initiation, Continuation, and Discontinuation

Initiation of a powered NPWT system (Initial therapeutic trial)

An initial therapeutic trial of not less than 2 weeks using a powered negative pressure wound therapy (NPWT) system, as part of a comprehensive wound care program that includes controlling factors (e.g., diabetes, nutrition, relief of pressure) may be considered medically necessary when ANY of the following are met:

ANY of the following

Chronic (> 90 days) stage III or IV pressure ulcers that have failed to heal despite optimal wound care when there is high-volume drainage that interferes with healing and/or when standard dressings cannot be maintained due to anatomic factors.
Wounds in individuals with underlying clinical conditions that are known to negatively impact wound healing, which are nonhealing (at least 30 days), despite optimal wound care. (Examples of underlying conditions include, but are not limited to diabetes, malnutrition, small vessel disease, and morbid obesity. Malnutrition must be addressed simultaneously with the NPWT.)
Traumatic or surgical wounds where there has been a failure of immediate or delayed primary closure, AND there is exposed bone, cartilage, tendon, or foreign material within the wound.

Provider Actions — Prior Auth, Documentation, and Billing

Prior Authorization

Therapeutic trial requirement (initial ≥14 days)

An initial therapeutic trial of powered NPWT of not less than 2 weeks is required prior to consideration of medical necessity for continued powered NPWT. Include documentation that the trial was at least 14 days and that it was performed as part of a comprehensive wound care program.

Affected procedure codes: 97605, 97606
Minimum trial duration: >= 14 days

Documentation Required

Comprehensive wound care program documentation

Providers must document that NPWT is part of a comprehensive wound care program. Required documentation includes evaluation and wound measurements by a licensed medical professional, use of dressings to maintain a moist wound environment, debridement when present, and evaluation/provision for adequate nutritional and vascular status.

Evaluation, care, and wound measurements documented by a licensed medical professional

Coding

Investigational; therefore, not covered (Procedure Codes)HCPCSNot Covered

A9272	Negative pressure wound therapy management, topical application of a negative pressure device to a wound for therapy (e.g., vacuum-assisted therapy), per day
97607	Negative pressure wound therapy (e.g., vacuum-assisted drainage), with dressing changes, including topical application(s), wound assessment, and instruction(s) for ongoing care, per day
97608	Negative pressure wound therapy with wound assessment, including topical application(s), and instruction(s) for ongoing care, per day

Covered when medically necessary (Procedure Codes)CPT|HCPCSCovered

97605	Negative pressure wound therapy (e.g., vacuum-assisted drainage) using disposable single-use pump, including dressing changes etc. (listed as covered when medically necessary in policy text)
97606	Negative pressure wound therapy management, topical application of a negative pressure device to a wound, complicated or extensive (mapping indicated in policy: .A7000 = 97606)
A7000	DME related mapping referenced in policy text (policy maps A7000 = 97606)
A7001	DME mapping referenced in policy text
E2402	Supply code referenced in policy text
K0743	HCPCS supply code referenced in policy text
K0744	HCPCS supply code referenced in policy text
K0745	HCPCS supply code referenced in policy text
K0746	HCPCS supply code referenced in policy text

Relevant ICD-10 diagnosis codes (examples listed)ICD-10

E08.621	Diabetes mellitus due to underlying condition with foot ulcer
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer
E10.621	Type 1 diabetes mellitus with foot ulcer
E10.622	Type 1 diabetes mellitus with other skin ulcer
E11.621	Type 2 diabetes mellitus with foot ulcer
E11.622	Type 2 diabetes mellitus with other skin ulcer
E11.A	Type 2 diabetes mellitus without complications in remission
E13.621	Other specified diabetes mellitus with foot ulcer

1–10 of 38

1/4

Listed ICD-10-CM diagnosis codes (non-pressure chronic ulcers, wounds, lacerations, punctures, dehiscence, infection, disruption)ICD-10Covered

1–10 of 188

1/19

Procedure codes moved to investigational table (mentioned)CPTExperimental

97607	Procedure code moved to investigational coding table per policy history and coding list
97608	Procedure code moved to investigational coding table per policy history and coding list

Background and Evidence Summary

Background: NPWT uses negative pressure to aspirate exudate and promote formation of granulation tissue. Devices include both powered systems and single-use (disposable) systems (for example, SNaP and PICO). Although multiple NPWT devices have been cleared by the FDA (510[k] cleared devices listed), no NPWT device has been cleared for use in infants and children. FDA safety communications (2009 alert and 2011 update) noted rare but serious adverse events including bleeding (the most serious events, including deaths) and wound infection related to retained dressing pieces; providers were advised to select patients carefully and monitor frequently.

Evidence	Summary
Diabetic lower-extremity ulcers RCTs / systematic reviews
Evidence sufficient to determine improvement in net health outcome (higher healing rates, fewer amputations) though risk of bias exists.
Portable single-use NPWT RCTs (PICO, SNaP)
RCTs show noninferiority for wound area reduction; evidence insufficient to conclude improvement in net health outcome for many indications.
Chronic pressure ulcers
RCTs low quality/high risk of bias; most populations inpatient; insufficient evidence for outpatient NPWT benefit.
Venous insufficiency ulcers
Limited inpatient evidence of faster healing with NPWT after grafting; no outpatient data showing net benefit; insufficient evidence.
Burns, traumatic/surgical wounds
Evidence mixed (RCTs, reviews, case series); insufficient to determine outpatient NPWT net health outcome benefit.
FDA Safety Communication
FDA updates (2009, 2011) noted rare but serious complications including bleeding and infection; no NPWT devices cleared for infants and children.
Systematic review
AHRQ Evidence Report/Technology Assessment and multiple systematic reviews summarized evidence and limitations; concluded variable quality and insufficient data for many outpatient indications.

Definitions

Definitions / Key terms:

- Comprehensive wound care program: documentation by a licensed medical professional of evaluation, care, and wound measurements; dressings to maintain a moist wound environment; debridement when present; and evaluation/provision for adequate nutritional and vascular status.

- Granulating tissue: formation of granule-like projections on the internal wound surface representing new capillaries that promote healing.

- Pressure (decubitus) ulcer stages: Stage I–IV descriptions and an "Unstageable" category (Stage III/IV denote full-thickness tissue loss; unstageable when base is obscured by slough or eschar).

- Vascularity: the state of blood vessel development and functioning in an organ or tissue.

- Chronic: wound duration defined for this policy as > 90 days (per 03/06/2025 update).

- INV (Investigational): single-use NPWT devices (powered or nonpowered) are categorized as investigational in this policy; additionally, procedure codes 97607 and 97608 have been moved to the investigational coding table.

Revision History

02/12/2021clarified

Frequency of monitoring changed from every 14 days to monthly; Length of Coverage section removed and Policy Guidelines deleted.

08/15/2024administrative

Administrative update: added/deleted ICD-10 codes from New Code Process effective 10/01/2024.

03/06/2025revised

Minor review: chronic wounds defined as greater than 90 days; single-use devices are now considered investigational (INV); procedure codes 97607 and 97608 moved to investigational coding table. (Marked as material changes.)

Policy Summary

PayerCapital Bluecross

PolicyNegative Pressure Wound Therapy in the Outpatient Setting

Policy CodePolicy MP 4.004

Change TypeRevisedadministrativeclarified

Effective DateOct 1, 2025

Next Review Date

SourceLink

On This Page

Continuation of powered NPWT (medical necessity after initial trial)

Continuation of the powered NPWT system, as part of a comprehensive wound care program, may be considered medically necessary following an initial 2-week therapeutic trial when ALL of the following are met:

ALL of the following

The initial 2-week therapeutic trial resulted in documented objective improvements in the wound (see examples below).
There is ongoing objective improvement during subsequent treatment.
Examples of objective improvement
- Development and presence of healthy granulation tissue.
- Progressive wound contracture and decreasing depth.
- Commencement of epithelial spread from the wound margins.

When continuation is considered investigational/not medically necessary

Continuation of powered NPWT is considered investigational/not medically necessary when ANY of the following occur:

ANY of the following

The therapeutic trial or subsequent treatment period has not resulted in documented objective improvement in the wound.
The wound has developed evidence of wound complications contraindicating continued NPWT.
The wound has healed to an extent that either grafting can be performed or the wound can be anticipated to heal completely with other wound care treatments.

Investigational / Not covered uses

The following uses are considered investigational / not covered:

ANY of the following

Therapeutic trials of powered NPWT systems for the treatment of other acute or chronic wounds except as specifically listed in medically necessary indications.
Use of single-use NPWT systems (powered or nonpowered) for the treatment of acute or chronic wounds, including but not limited to diabetic, venous, surgical, and traumatic wounds.

Contraindications (per FDA and policy guidelines)

Contraindications to the use of negative pressure wound therapy (NPWT) systems include the following (ALL are contraindications):

ALL of the following

Necrotic tissue with eschar.
Untreated osteomyelitis.
Nonenteric and unexplored fistulae.
Malignancy in the wound.
Exposed nerve.
Exposed anastomotic site.
Exposed organ.

Monitoring and expected healing benchmarks

Monitoring and expected healing benchmarks:

ALL of the following

Continuation of healing during use of the NPWT system should be monitored on a frequency of not less than every 14 days.
Operational: monitoring must be by a trained practitioner in an appropriate care setting.
Complete healing would normally be anticipated if ALL of the following are met
- All bone, cartilage, tendons, and foreign material are completely covered.
- Healthy granulation is present to within 5 mm of the surface.
- Wound edges are reduced to 2 cm in width or diameter.

Definitions/Policy changes (as noted in history)

Definitions / Policy changes:

ALL of the following

Powered NPWT systems: electrically powered devices that provide adjustable negative pressure and are intended for repeated use as part of outpatient wound management.
Single-use NPWT systems: disposable, typically nonpowered or battery-powered devices intended for single patient use; considered investigational for acute and chronic wounds under this policy.
Policy change notes: Effective 2025-10-01 this policy clarifies initiation (minimum 2-week therapeutic trial), documents continuation criteria requiring objective improvement, reiterates single-use NPWT systems as investigational, and aligns contraindications and monitoring frequency with FDA guidance and prior policy history.

Documentation Required

Objective improvement documentation for continuation

For continuation of powered NPWT after the initial trial, document objective wound improvements. Examples of acceptable objective improvements include development/presence of healthy granulation tissue, progressive wound contracture with decreasing depth, and commencement of epithelial spread from wound margins.

Healthy granulation tissue formation
Progressive wound contracture and decreased wound depth
Commencement of epithelialization (epithelial spread from wound margins)

Denial Risk

Investigational devices and single-use NPWT — denial risk

Claims for single-use NPWT systems (powered or nonpowered) and therapeutic trials outside the policy's listed medically necessary indications are considered investigational and are at risk for denial. Providers should be aware that certain procedure/supply codes are designated investigational and may be denied.

Affected procedure codes at denial risk: A9272, 97607, 97608
Warning: single-use (disposable) NPWT systems and off-indication therapeutic trials are investigational and may be denied